← All trials
NCT01619761
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2013
- Primary completion
- May 1, 2019
- Completion date
- May 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 13
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
- CelgeneCollaborator
- American Cancer Society, Inc.Collaborator
- CLL Global Research FoundationCollaborator
Drugs studied
Indications studied
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Biphenotypic, Acute
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Lymphoma, B-Cell
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.